Preferred Label : Allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced Cord Blood-derived Natural Killer
Cells TAK-007;
NCIt synonyms : iC9/CAR.19/IL15-transduced CB-NK Cells; iC9/CAR-CD19-CD28-zeta-2A/IL-15 CB-NK Cells; CAR-CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK Cells; iC9/CAR19/IL15-transduced CB-NKs; UCB-derived CAR-CD19-CD28-zeta-2A-iCasp9-IL15 Engineered NK Cells; Allogeneic iC9/CAR19/IL15-transduced CB-NK Cells;
NCIt definition : A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells
(NKs) transduced with a retroviral vector expressing interleukin-15 (IL-15) and encoding
a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA)
CD19 that is coupled to the co-stimulatory domains of CD28 and to the zeta chain of
the TCR/CD3 complex (CD3-zeta), and is linked to the suicide gene inducible caspase
9 (iCasp9; iC9), with potential immunomodulating and antineoplastic activities. Upon
transfusion, the allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced CB-NKs TAK-007
recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells.
The iCasp9 safety switch consists of a full-length caspase 9, including its caspase
recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation
(FKBP12-F36V). If the administered NK cells lead to unacceptable side effects, the
chemical homodimerizer AP1903 can be administered; AP1903 binds to the FKBP12-F36V
drug-binding domain, activates caspase 9, and results in apoptosis of the administered
NK cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all
B-cell lineage malignancies. IL-15 enhances the cytotoxic effect of the NK cells.;
Molecule name : TAK-007; TAK 007;
NCI Metathesaurus CUI : CL550854;
Origin ID : C148215;
UMLS CUI : C5666853;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
